RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.